Key result
Sleeve gastrectomy with transit bipartition resulted in a mean total weight loss of 20.2% (95% CI 19.5-20.8) and complete type 2 diabetes remission in 79.2% of patients at 2 years.
Why the study?
It was unclear whether obese patients with type 2 diabetes of varying duration and severity experience equivalent weight loss and diabetes remission after sleeve gastrectomy with transit bipartition.
Does sleeve gastrectomy with transit bipartition improve weight loss and type 2 diabetes remission in obese patients with type 2 diabetes?
Cohort (n=355)
Does sleeve gastrectomy with transit bipartition improve weight loss and type 2 diabetes remission in obese patients with type 2 diabetes?
Effect estimate: Mean TWL 20.2% (95% CI 19.5-20.8)
p-value: p=<0.001
Sleeve gastrectomy with transit bipartition provides excellent weight loss and high rates of type 2 diabetes remission at 2 years, regardless of preoperative diabetes duration and severity.
May support transit bipartition in obese T2D; hypothesis-generating pending randomized confirmation.
INTRODUCTION: This study examined whether 355 obese patients with type 2 diabetes (T2D) of varying duration and severity experienced equivalent weight loss and T2D remission following a newer sleeve gastrectomy (SG) procedure - SG with transit bipartition (SG-TB). METHODS: Primary outcomes were changes in body mass index (BMI), total weight loss (TWL), excess BMI loss (EBMIL), A1C, and diabetes medication use through 24 months. RESULTS: Between December 2015 and December 2019, 399 patients who underwent SG-TB reached the 2-year time point. Follow-up was possible in 355 patients (89.0%): 206 females (58.0%), mean age 51.5 years (24.0-73.0), BMI 34.0 kg/m2 (28.0-50.5), and T2D duration 12.0 years (4.0-37.0). At 2 years, total sample respective mean TWL and EBMIL were 20.2 ± 6.1% (95% CI: 19.5, 20.8) and 87.7 ± 35.2% (84.1, 91.4) corresponding to mean BMI change of 7.0 ± 2.7 kg/m2 (6.7, 7.3) (p < 0.001). T2D duration and severity subgroups experienced comparable BMI and A1C change from baseline (p < 0.001); 281 (79.2%) maintained complete remission. ANOVA showed significant mean increases in vitamin D, calcium, and albumin: overall complication rate, 10.2%; no mortality. DISCUSSION/CONCLUSION: In 355 patients with obesity who underwent SG-TB, excellent weight loss, T2D, and nutritional outcomes were seen at 2-year follow-up regardless of preoperative T2D duration and severity.
No takes yet. Share an insight, caveat, or question.
Al et al. (2022) conducted a cohort in Obesity and type 2 diabetes (n=355). Sleeve gastrectomy with transit bipartition (SG-TB) was evaluated on Changes in body mass index (BMI), total weight loss (TWL), excess BMI loss (EBMIL), A1C, and diabetes medication use through 24 months (Mean TWL 20.2%, 95% CI 19.5-20.8, p=<0.001). Sleeve gastrectomy with transit bipartition resulted in a mean total weight loss of 20.2% (95% CI 19.5-20.8) and complete type 2 diabetes remission in 79.2% of patients at 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: